Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy (after discontinuation of anti-androgen therapy) * Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR * ECOG performance status 0-1 Exclusion Criteria: * Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer * History of deep vein thrombosis or pulmonary embolus * Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while on study is acceptable. * History of a bleeding disorder or recent clinically significant bleeding * Seropositive for HIV * History of Hepatitis B, Hepatitis C, or chronic liver disease * Prior gene therapy or immunotherapy * Prior chemotherapy for prostate cancer * Radiation therapy within 4 weeks of the first treatment. * History of myocardial infarction within 6 months of the first treatment * History of cerebrovascular accident * History of previous malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years * Evidence of active prostatitis * Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80